MOISES ESQUENAZI: Open Payments
NPI 1659743797 · SOUTH MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,839 in 140 payments from 14 companies in 2025. Trend: 2023 $1,020 · 2024 $2,498 · 2025 $2,839
Food & beverage: $2,839
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 17 | $463 |
| ABBVIE INC. | 35 | $445 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $366 |
| Indivior Inc. | 11 | $299 |
| Otsuka America Pharmaceutical, Inc. | 12 | $279 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $223 |
| Janssen Pharmaceuticals, Inc | 12 | $189 |
| Vanda Pharmaceuticals Inc. | 7 | $185 |
| E.R. Squibb & Sons, L.L.C. | 5 | $113 |
| Almatica Pharma LLC | 3 | $72 |
Products named: Auvelity, VRAYLAR, CAPLYTA, SUBLOCADE, REXULTI, TRINTELLIX, INVEGA SUSTENNA, HETLIOZ.
Industry payments across FL — which companies pay providers there.
